RXRX Q3 2022 Earnings — Recursion Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

RXRXRecursion Pharmaceuticals, Inc.

$2B

Q3 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$13M+422.1% YoY

Gross Profit

-$2M-18.0% margin

Operating Income

-$63M-479.4% margin

Net Income

-$60M-463.1% margin

EPS (Diluted)

$-0.34

QoQ Revenue Growth

+70.6%

Cash Flow

Operating Cash Flow

-$55M

Free Cash Flow

-$63M

Stock-Based Comp.

$9M

Balance Sheet

Total Assets

$612M

Total Liabilities

$223M

Stockholders' Equity

$388M

Cash & Equivalents

$455M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$13M	$3M	+422.1%
Gross Profit	-$2M	$3M	-194.2%
Operating Income	-$63M	-$46M	-34.8%
Net Income	-$60M	-$47M	-27.4%

Revenue Segments

License and Service

$13M99%

Grant

$107,0001%